Jack Allen
Stock Analyst at Baird
(1.51)
# 3,419
Out of 4,984 analysts
42
Total ratings
40.62%
Success rate
-7.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Maintains: Neutral | $0.25 → $1 | $1.52 | -34.21% | 4 | Jun 27, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $0.95 | +321.05% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.13 | +696.46% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.31 | +218.27% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $14.24 | +180.90% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $76.42 | +38.71% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $12.41 | +45.04% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $21.55 | +735.46% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $1.73 | +362.43% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $59.07 | -11.97% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $33.42 | +151.38% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.90 | +175.86% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.39 | +259.71% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.08 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.26 | +111.27% | 1 | Oct 7, 2021 |
Vor Biopharma
Jun 27, 2025
Maintains: Neutral
Price Target: $0.25 → $1
Current: $1.52
Upside: -34.21%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $0.95
Upside: +321.05%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.13
Upside: +696.46%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.31
Upside: +218.27%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $14.24
Upside: +180.90%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $76.42
Upside: +38.71%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $12.41
Upside: +45.04%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $21.55
Upside: +735.46%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $1.73
Upside: +362.43%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $59.07
Upside: -11.97%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $33.42
Upside: +151.38%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.90
Upside: +175.86%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.39
Upside: +259.71%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.08
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.26
Upside: +111.27%